Skip to main content
Eye logoLink to Eye
. 2011 Aug 19;25(11):1457–1464. doi: 10.1038/eye.2011.196

Clinical characteristics of optic neuritis in Taiwanese children

M-H Sun 1,2, H-S Wang 2,3, K-J Chen 1,2, W-W Su 1,2, P-Y Hsueh 1,2, K-K Lin 1,2, L-Y Kao 1,2,*
PMCID: PMC3213655  PMID: 21852809

Abstract

Purpose

To document the etiology, clinical presentation, and visual prognosis of optic neuritis in Taiwanese children.

Methods

Retrospectively reviewed children younger than 18 years old with optic neuritis in Chang Gung Memorial Hospital and Chang Gung Children's Hospital from 1998 to 2009.

Results

There were 24 children (38 eyes) with optic neuritis in that period. Overall, 14 patients (58.3%) were female and 10 patients (41.7%) were male. In total, 14 patients (58.3%) had bilateral involvement, and 10 patients (41.7%) had unilateral involvement. Out of 38 eyes, 24 (63.2%) had disc swelling. Out of 24 patients, 21 (87.5%) underwent intravenous steroid therapy (10 to 30 mg/kg/day) for 3–5 days, and followed by an oral taper. Out of 24 patients, 20 (83.3%) achieved final visual acuity (VA) of 20/40 or better. However, a poor visual outcome (four patients) (VA<20/40) was correlated with pale disc at presentation (P=0.002, Pearson χ 2-test) and age older than 10 years (P=0.012, Fisher's exact test). Five patients were diagnosed with acute disseminated encephalomyelitis (ADEM) (21%), and three patients were diagnosed with multiple sclerosis (MS) (12.5%). Patients with ADEM did not have a better visual outcome than patients with MS (P=0.643, Fisher's exact test).

Conclusions

Visual recovery from optic neuritis was favorable in Taiwanese children. A poor visual outcome was correlated with pale disc at presentation and patients' age older than 10 years. ADEM is the most common associated systemic disease; MS is relatively rare.

Keywords: children, optic neuritis, ADEM

Introduction

The visual prognosis of patients with optic neuritis has been well studied by the Optic Neuritis Treatment Trial (ONTT).1, 2, 3 Benefit from treatment with intravenous steroid in prevention from multiple sclerosis (MS) has also been extensively analyzed.4, 5, 6, 7 However, these studies were mostly confined to young adults. Optic neuritis in children is considered to be a totally different entity in contrast to adults. Children with optic neuritis usually experience better visual recovery, they also have more bilateral involvement and optic disc swelling, and carry a relatively low risk of subsequent MS as well.8, 9, 10 However, there have been accumulating reports with different clinical characteristics of optic neuritis and MS in Europe,11, 12 North America,8, 9, 13 and Asia.14, 15, 16, 17 Herein we report a retrospective study to evaluate the clinical characteristics of children with optic neuritis in Taiwan. Meanwhile, the specific aim of this study was to statistically document the factors relevant to visual prognosis in optic neuritis in children.

Patients and methods

The medical records of all patients younger than 18 years old, who came to Linkou Chang Gung Memorial Hospital and Chang Gung Children's Hospital from 1998 to 2009, with a diagnosis of optic neuritis were retrospectively reviewed. This study was approved by the Institutional Review Board at Chang Gung Memorial Hospital. The diagnosis of optic neuritis was made on the basis of history of visual loss and some of the clinical findings including afferent pupillary defect, visual field defect, optic disc appearance, color vision defect, and abnormal visual-evoked potentials. Patients with hereditary optic neuropathy, systemic vascular diseases, compressive optic neuropathy, and malignancy were excluded from this study. Optic neuritis was recorded as unilateral or bilateral. Bilateral simultaneous disease was defined as both eyes being affected within 1 month of each other, and bilateral recurrent disease was defined as one or both eyes being affected more than once.

Information about the sex, age of onset, laterality (unilateral or bilateral), initial visual acuity (VA), final VA, cerebrospinal fluid (CSF) findings, therapy, recent infections and immunizations, image study including computer tomography (CT) or magnetic resonance imaging (MRI), and associated systemic diseases such as MS or acute disseminated encephalomyelitis (ADEM) was obtained.

For statistical analysis, the initial VA and final VA were taken as best-corrected VA (BCVA). A logarithmic transformation of decimal VA was used a scattergram. Eyes without formed vision were classified into one of four low-vision categories, which were assigned decimal equivalents as follows: counting fingers=0.00500; hand motion=0.00250; light perception=0.00125; and no light perception=0.00100.18 The logarithm of reciprocal decimal VA was used to approximate the logarithm of minimal angle of resolution (log MAR). All statistical analyses were conducted using SPSS software (Standard Windows version 15.0, SPSS, Chicago, IL, USA). All P-values quoted were two-tailed and were considered statistically significant when they were less than 0.05.

Results

As shown in Table 1, 24 patients (38 eyes) were included in this study; their ages ranged from 5 to 17 years. The mean age at presentation was 10.08±4.15 years. Follow-up period ranged from 1 week to 12 years, with a mean of 14.01 months (median: 2.5 months). There were 14 female patients (58.3%) and 10 male patients (41.7%). Fourteen patients (58.3%) had bilateral disease, and ten patients (41.7%) had unilateral disease. In addition, 14 patients (58.3%) had afferent pupillary defect, and 24 eyes (63.2%) had disc swelling. Of 16 eyes (42.1%) performed visual field examination, 14 eyes had visual field defect, and generalized suppression was the most common type. Of 21 eyes (55.3%) performed color vision test, 19 eyes had color vision defect. Of 23 eyes (60.5%) performed visual evoked potential test, 19 eyes had abnormal visual evoked potential. Out of 24 patients, 21 (87.5%) underwent intravenous steroid therapy. Of these 21 patients, 19 patients received methylprednisolone therapy (10–30 mg/kg/day) for 3–5 days, and followed by oral prednisolone 1 mg/kg/day for 2–4 weeks, the other 2 patients received dexamethasone therapy (5 mg, q6 h for 7 days, followed by tapering from q8 h, q12 h to qd). Of 10 patients (41.7%) performed CSF analysis, 8 patients had normal CSF findings. Of seven patients further tested for oligoclonal band in CSF and calculated IgG index, none had oligoclonal band. One patient had IgG index over 0.66 (0.792) and developed MS. In addition, two patients diagnosed with ADEM had proof of recent viral infection by CSF study and by serological test, respectively. These details of patients' information are summarized in Table 2.

Table 1. Demographics and clinical features of patients.

Total eyes 38
Total patients 24
   
Age 5–17 years
 Mean 10.08±4.15
   
Follow-up time 1 week−12 years
 Mean 14.01 months
 Median 2.5 months
   
Sex
 Male, n (%) 10 (41.7)
 Female, n (%) 14 (58.3)
   
Laterality
 Bilateral, n (%) 14 (58.3)
 Unilateral, n (%) 10 (41.7)
   
Pupillary function test
 RAPD positive, n (%) 14 (58.3)
 RAPD negative, n (%) 10 (41.7)
   
Disc appearance at presentation  
 Swelling, n (%) 24 eyes (63.2)
 Normal, n (%) 11 eyes (28.9)
 Pale, n (%) 3 eyes (7.9)
   
Visual field examination 16 eyes
 Generalized suppression 11
 Cecocentral scotoma 1
 Hemianopsia 1
 Superior suppression 1
 Normal 2
   
Color vision test 21 eyes
 Defect 19
 No defect 2
   
Visual evoked potential test 23 eyes
 Abnormal 19
 Normal 4
   
Steroid therapy 21 patients
 Methylprednisolonea 19
 Dexamethasoneb 2
   
CSF study 10 patients
 Normal 8
 Oligoclonal band 0
 IgG index>0.66c 1
 Positive for virus infection 1

Abbreviations: CSF, cerebrospinal fluid; RAPD, relative afferent papillary defect.

a

Intravenous methylprednisolone (10–30 mg/kg/day) q6 h for 3–5 days, followed by oral prednisolone (1 mg/kg/day) for 2–4weeks.

b

Intravenous dexamethasone (5 mg) q6 h for 7 days, followed by q8 h for 2 days, q12 h for 2 days, and qd for 2 days.

c

Normal IgG index<0.66.

Table 2. Summary of cases.

Patient Sex/age/ laterality Follow-up (weeks) Initial VA Final VA Disc finding Image study Systemic association Steroid therapy Febrile illness
1 M/11 years/bilateral 4 (od) CF/20 cm (os) 20/1000 (od) 20/600 (os) 20/600 Pale Normal CT: normal No 13.5 mg/kg/day No
2 F/6 years/unilateral 576 (od) LS (−) (od) 20/20 Normal MRI: multifocal enhanced brain lesion No Nil Yes
3 M/7 years/unilateral 144 (od) HM/10 cm (od) 20/30 Pale MRI: normal No Nil No
4 M/17years/bilateral 2 (od) 20/200 (os) 20/200 (od) 20/25 (os) 20/20 Normal Normal No No 15 mg/kg/day No
5 F/5 years/unilateral 4 (od) 20/28 (od) 20/25 Normal No No Nil No
6 F/6 years/ bilateral 72 (od) CF/1m (os)CF/2m (od)20/40a (os) 20/100a Swelling Swelling MRI: white matter lesion MS 20 mg/kg/day No
7 F/6 years/unilateral 48 (od) LS(−) (od) 20/22a Swelling MRI: swelling of right optic nerve, white matter lesion ADEM 16 mg/kg/day Yes
8 F/10 years/bilateral 2 (od) 20/1000 (os) 20/1000 (od) 20/20 (os) 20/20 Swelling Swelling CT: normal No 10 mg/kg/day No
9 F/7 years/unilateral 4 (od) LS(−) (od) 20/25 Swelling MRI: normal No 25 mg/kg/day No
10 M/11 years/bilateral 1 (od) 20/60 (os) LS(+) (od) 20/30 (os) 20/50 Swelling Swelling MRI: normal No 28.5 mg/kg/day No
11 F/9 years/ bilateral 2 (od) 20/285 (os) LS(−) (od) 20/20 (os) 20/20 Normal Normal MRI: normal No 0.74 mg/kg/dayb No
12 M/16 years/bilateral 1 (od) 20/2000 (os) 20/600 (od) 20/25 (os) 20/30 Swelling Swelling No No 19.4 mg/kg/day No
13 M/9 yr/ unilateral 50 (os)20/60 (os)20/20 Swelling MRI: optic nerve enhancement No 16.7 mg/kg/day No
14 F/6 yr/ bilatearl 96 (od) LS(−) (os)20/400 (od)20/20 (os)20/20 Swelling Swelling MRI: subcortical white matter lesion MS 30.68 mg/kg/day No
15 F/6 yr/ bilateral 192 (od)CF/60 cm (os)CF/5 cm (od)20/20 (os)CF/5 cm Swelling Swelling MRI: normal No 25.3 mg/kg/day No
16 M/6 yr/ bilateral 4 (od)LS(+) (os)LS(+) (od)20/20 (os)20/20 Swelling Swelling MRI: multifocal white and gray matter lesion ADEM 30 mg/kg/day Yes
17 M/17 yr/unilateral 32 (os)20/600 (os)20/60 Normal MRI: enhancement of optic nerve No 17.1 mg/kg/day No
18 F/16 yr/ bilateral 36 (od)20/100 (os)20/40 (od)20/100c (os)20/300c Pale Pale Demyelination lesion involving brain stem and upper spinal cord MS 16.1 mg/kg/day No
19 F/10 yr/ bilateral 8 (od)CF/20 cm (os)CF/1m (od)20/20 (os)20/20 Swelling Swelling MRI: enhancement of optic nerve ADEM 0.44 mg/kg/dayb No
20 M/8 yr/ bilateral 3 (od)20/100 (os)HM/10 cm (od)20/20 (os)20/25 Swelling Swelling MRI: normal No 16.1 mg/kg/day No
21 F/15 yr/ bilateral 16 (od)20/200 (os)20/200 (od)20/20 (os)20/20 Normal Normal MRI: normal No 17.5 mg/kg/day No
22 F/17 yr/ unilateral 28 (od)20/25 (od)20/50 Pale MRI: multiple demyelination ADEM 12.6 mg/kg/day No
23 F/12 yr/ unilateral 8 (od)LS(−) (od)20/20 Normal MRI: multiple spinal cord and pontine lesion ADEM 16.1 mg/kg/day No
24 M/9 yr/ unilateral 12 (od)CF/20 cm (od)20/40 Swelling CT: normal No 26.9 mg/kg/day No

Steroid therapy: intravenous methylprednisolone for 3–5 days, followed by oral prednisolone, 1 mg/kg/day, for 2–4 weeks.

a

Recurrent one time.

b

Intravenous dexamethasone (5 mg) q6 h for 7 days, followed by q8 h for 2 days, q12 h for 2 days, and qd for 2 days.

c

Recurrent two times.

Effect of initial VA on final VA

There was a significant difference between initial VA (logMAR) and final VA (logMAR) in our patients (P≤0.001, Wilcoxon signed-ranks test), indicating good visual recovery in pediatric patients with optic neuritis. Initial VA ranged from 20/20 to no light perception. Out of 38 eyes, 19 (50%) had initial VA better than 20/4000 (above counting fingers) at presentation, and 19 of 38 eyes (50%) had initial VA worse than 20/4000 (counting fingers or below) at presentation. Eyes with initial VA better than 20/4000 did not have better final VA (VA ≥20/40) than those with initial VA worse than 20/4000 (P=1.00, Fisher's exact test).

Effect of gender on final VA

In this study, 20 of 24 patients (83.3%) achieved final VA of 20/40 or better. Of the 20 patients with final VA of 20/40 or better, 12 patients were female and 8 patients were male. Statistical analysis for final visual outcome in female group vs male group did not demonstrate a significant difference (P=0.563, Fisher's exact test).

Effect of laterality on final VA

Out of 14 patients, 12 (85.7%) in the bilateral group attained final VA of 20/40 or better, 8 of 10 patients (80%) in the unilateral group achieved final VA of 20/40 or better. The statistical analysis revealed no significant difference in visual outcome between patients with bilateral diseases and unilateral diseases (P=0.563, Fisher's exact test).

Effect of disc appearance on final VA

The values of final VA (logMAR) in the three groups were significantly different (P=0.025, Kruskal–Wallis test). Non-parametric post-hoc comparisons indicated that final VA in the pale disc group was significantly poorer than that in the swelling disc group (P=0.016) and normal disc group (P=0.022). There was no difference in final VA between the swelling disc group and normal disc group (P=0.352) (Mann–Whitney U-test). Out of 24 eyes, 20 (83.3%) with swelling disc at presentation achieved final VA of 20/40 or better, 9 of 11 eyes (81.8%) with normal disc at presentation achieved final VA of 20/40 or better, and none of 3 eyes (0%) with pale disc at presentation attained final VA of 20/40 or better. There was a statistically significant trend toward a poorer visual outcome in eyes with pale disc at presentation (P=0.005, Pearson χ2-test).

Effect of age at presentation on final VA

Subgroup analysis was performed on the visual outcome in patients 10 years of age or younger and those 11 years of age or older at presentation. All of the 15 patients (100%) who were 10 years of age or younger achieved final VA of 20/40 or better; five of nine patients (55.6%) who were 11 years of age or older achieved final VA of 20/40 or better. There was a statistically significant better visual outcome in children younger than 10 years of age (P=0.012, Fisher's exact test).

Effect of systemic association on final VA

Five patients were diagnosed with ADEM, and four of these five patients (80%) achieved final VA of 20/40 or better. Three patients were diagnosed with MS, and two of these three patients (66.7%) attained final VA of 20/40 or better. Statistical analysis for visual outcome in ADEM vs MS group, and patients with ADEM vs patients without ADEM demonstrated that there were no significant difference (P=0.643, and 0.635, respectively, Fisher's exact test).

Regression analysis for final VA

We further divided patients into unilateral and bilateral groups for assessment of all above factors in final VA. In the unilateral group, there is a significant relationship between age and final VA, with a 1-year increase in age being associated with an increase of 0.034 log MAR in final VA (P=0.013, multiple linear regression analysis) after adjusting for initial VA. Meanwhile, the relationship between disc appearance at presentation and final VA is highly significant in the bilateral group, with a decrease of 1.646 log MAR in final VA in normal disc group (P=0.001) and a decrease of 1.489 log MAR in final VA in swelling disc group (P=0.002), after adjusting for initial VA (multiple linear regression analysis).

Neuroimaging

Of 24 patients, MRI of the brain was performed in 19 patients. Computed tomography of the brain was performed in three patients. Out of 19 patients, 11 (57.89%) had abnormal MRI findings, including only optic nerve enhancement in 2 patients, combined optic nerve enhancement with cerebral white matter lesion in 2 patients, and multiple cortical white matter lesions in the brain or spinal cord in 7 patients. In eight patients with normal MRI of the brain, the images all revealed well visualization of bilateral optic nerve and optic pathway without definite abnormal signal intensity or contrast enhancement. Interestingly, of these eight patients with normal optic nerve appearance in MRI, five patients (62.5%) had disc swelling, and the other three patients (37.5%) had normal optic disc. In contrast, of four patients having abnormal enhancement of optic nerve in MRI in this study, two patients (50%) had disc swelling and the other two patients (50%) had normal optic disc. Taken together, it indicated that appearance of optic disc might not correlate well with optic nerve appearance in image study. Of 11 patients having abnormal MRI findings, 8 patients (72.7%) achieved final VA of 20/40 or better. All three patients performing CT of the brain had normal findings. Of a total 11 patients having normal image study (MRI or CT), 10 patients (90.9%) achieved final VA of 20/40 or better. There was a trend toward better visual outcome in children with normal image study, but there was no statistically significant difference (P=0.586, Fisher's exact test). The factors for visual prognosis in pediatric optic neuritis in this study are summarized in Table 3.

Table 3. Factors for visual prognosis in pediatric optic neuritis.

Factors   No. of patients or eyes (n) No. of patients or eyes with final VA>20/40 P-value
Initial VA VA>20/4000 19 (eyes) 15 (eyes) 1.000
  VA<20/4000 19 (eyes) 14 (eyes)  
         
Sex Male 10 8 0.563
  Female 14 12  
         
Laterality Unilateral 10 8 0.563
  Bilateral 14 12  
         
Disc appearance Pale 3 (eyes) 0 (eyes) 0.005
at presentation Normal 11 (eyes) 9 (eyes)  
  Swelling 24 (eyes) 20 (eyes)  
         
Age Age ≤10 years 15 15 0.012
  Age>10 years 9 5  
         
Systemic association ADEM 5 4 0.643
  MS 3 2  
         
Neuroimaging (MRI or CT) Normal 11 10 0.586
  Abnormal 11 8  

Discussion

The visual prognosis and clinical features of pediatric optic neuritis has been described previously.8, 11, 12, 14, 15, 17, 19 According to these reports, 77–90% of patients attained final VA of 20/40 or better. In addition, optic neuritis in childhood had more bilateral, female involvement, disc swelling at presentation, and was frequently associated with preceding viral infection. In our study, 83.3% of our patients achieved final VA of 20/40 or better, suggesting favorable visual recovery in Taiwanese children. Our study further confirms previous clinical features of optic neuritis in children such as more bilateral, female involvement and disc swelling at presentation (Table 4). However, older mean age, lower preceding febrile illness, and a relatively lower development rate of MS were noted in Taiwanese children. ADEM is the most common associated systemic disease in current study.

Table 4. Comparison of ocular findings of previous studies with our findings.

  No.of patients Mean age (in years) Female (%) Bilateral (%) Preceding viral illness Final VA≧20/40 Disc swelling Multiple sclerosis No. of patients receiving systemic steroid
Present study 24 10 58.3 58.3 29.2 83.3 63.2 12.5 87.5
Kennedy and Carroll13 30 9.5 63 60 47   73 27 0
Kriss et al12 39 8.6 74 74 46 78 74 15 0
Riikonen et al11 21     62   90 76 43 0
Visudhiphan et al14 22 7.1 54.5 41 23 90 45 9.1 100
Brady et al8 25 9.4 52 54 48 77   16 84
Morales et al9 15 9.8 60 66 66 58.3 64 26 73
Hwang et al15 23 8.9 43 87 39 79 42 4 57
Mizota et al17 41 9.4 56 49 39 90 74 31.7 90.2
Jo et al19 20 6.5 85 65 40 80 75.8 25 75

Accumulating evidences have reported some factors relevant to better visual outcome in pediatric optic neuritis. For instance, unilateral involvement,9 normal MRI of the brain, and children 6 years of age or younger appeared to have a better visual prognosis.8 Compared with a previous study, there was no significant difference in visual outcome between children with unilateral involvement and bilateral involvement in our study. Although we also found a trend toward children with normal image study seeming to have a better visual outcome, there was no statistically significant difference. Nevertheless, we demonstrated that children younger than 10 years old significantly had a better visual prognosis. Furthermore, the younger the age, the better the final VA was in children with unilateral involvement as shown by regression analysis.

Optic atrophy has been identified in 85% of pediatric optic neuritis and does not have a strict correlation with VA.20 In our study, we found that children with pale disc at presentation significantly had a poorer visual outcome than children with normal or swelling optic disc at presentation. In addition, we also found that disc changes at presentation in bilateral disease were more important for predicting final VA. Patients with pale disc at presentation significantly had poor final VA; it is possible that pale disc at presentation might result from a previous unknown episode of optic neuropathy or delayed diagnosis of optic neuritis. In this study, one patient (number 18) experienced three episodes of optic neuritis in each eye. This patient ended up with pale optic disc and showed less favorable visual recovery compared with the other two patients (number 6 and 7) who experienced two episodes of optic neuritis. Therefore, the number of attacks of optic neuritis might be also an important factor for less favorable visual recovery. However, significant improvement of final vision was noted in most of our patients, regardless of initial vision, indicating the nature of better visual recovery in pediatric optic neuritis.

ADEM is a monophasic, multifocal, inflammatory disease of the central nervous system, and is considered to be a demyelinating illness of probable autoimmune etiology. It often occurs after recent viral infections or vaccination,21 but it can also develop without an apparent preceding condition.22 The acute neurological signs and symptoms may include headache, fever, vomiting, altered level of consciousness, seizures, motor and/or sensory deficits, cerebellar ataxia, and cranial nerve palsy.23, 24 Of five patients with ADEM in our study, two patients (40%) had fever, one patient (20%) had seizure, and two patients (40%) had preceding viral infection.

Optic neuritis is not uncommon in children with ADEM.25, 26 Optic neuritis in children with ADEM often is bilateral and associated with optic disc edema.27, 28 Meanwhile, the efficacy of intravenous steroid therapy was proved to be beneficial for ADEM.23, 24, 26, 29 Excellent response to steroid therapy in visual improvement and reduction of demyelinating lesions on MRI without recurrence in children with ADEM have also been reported.27, 28, 30 In our study, disc swelling at presentation was noted in three of five patients (60%) with ADEM, and bilateral optic neuritis was noted in two of five patients (40%) with ADEM. In addition, all of the patients with ADEM received steroid pulse therapy. Four of five patients (80%) with ADEM achieved final VA of 20/20, and the other one patient achieved a final VA of 20/50. Our results seem to be comparable to previous reports. However, the limitation of our study was that most of our patients received intravenous steroid pulse therapy and there was no control group for comparison. It is still unknown whether intravenous steroid pulse therapy had a beneficial effect on visual recovery in pediatric optic neuritis, and in pediatric optic neuritis with ADEM.

The risk for developing MS after optic neuritis in children has been well studied. Lucchinetti et al31 reported that 13% of the patients with isolated optic neuritis had progressed to clinically or laboratory-supported definite MS by 10 years of follow-up, 19% by 20 years, 22% by 30 years, and 26% by 40 years. Meanwhile, the presence of bilateral sequential or recurrent optic neuritis increased the risk of developing MS. In addition, the presence of HLA-DR2 antigens,11 and unilateral disease have also been reported to be the other risk factors.9, 11 However, the rate of developing MS after pediatric optic neuritis also varied with race (Table 4). In comparison with other Asian countries, the rate of developing MS was 12.5% in our study, which was higher than Korean (4%),15 and Thai (9.1%),14 but was much lower than that reported in Japanese (31.7%),17 and another recent Korean study (25%).19 One of the reasons for wide range of conversion rate in each study might be due to different follow-up period. Two of three patients who developed MS in our study had concurrent bilateral papillitis, the third patient had bilateral sequential and recurrent retrobulbar optic neuritis. Our finding was compatible with the observation from previous reports.8, 31 In this study, all these three patients with MS had bilateral optic neuritis, indicating that a bilateral disease might be a risk factor for developing MS.

The differentiation between MS and ADEM has an important prognostic implication, but is sometimes difficult. MS frequently recurs and results in progressive deterioration over many years, whereas ADEM is usually a monophasic disease from which there is generally complete recovery. In addition, MS is rarely associated with a preceding viral infection.32 MRI is the imaging of choice in diagnosis of ADEM, and is beneficial in the distinction from MS.33 In our study, the visual outcome in the ADEM group was not different from that in the MS group, which might be due to too small a number of patients in these two groups to achieve a statistically significant difference. Further investigation for collecting more patient number in these two groups and a prospective data collection for a considerable length of time should be needed.

There are some drawbacks in this study. First, the follow-up period was very wide. Overall, 13 patients (54.2%) were followed up within 3 months, 18 patients (75%) were followed up within 12 months, and 21 patients (87.5%) were followed up within 24 months. Of 13 patients with a follow-up period less than 3 months, 12 patients had final VA better than 20/40. We found that children with better visual recovery seemed to be prone to loss of follow-up. Insufficient follow-up time could lead to under estimation of the development of MS. Second, the type of treatment administered and the duration of time given were different between ophthalmologists and neurologists. The ophthalmologist usually followed the recommendations from the ONTT study to treat children with optic neuritis; however, the pediatric neurologist might not manage children in ways consistent with the ophthalmologist in clinical practice, which was also reported in a previous study.34 The main reason might be because of no standard guidelines from evidence-based research like the ONTT study in treating pediatric patients with optic neuritis. Nevertheless, intravenous methylprednisolone (10–30 mg/kg/day × 3–5 days) then taper from oral prednisolone for at least 4 weeks is still recommended to hasten visual recovery in children with optic neuritis.20 Finally, MRI of the brain is the gold standard imaging procedure for optic neuritis because it is much more powerful in predicting the risk of progression to MS compared with the presence of HLA-DR2 or CSF oligoclonal IgG band.35 However, CT of the brain was still performed in three patients because of the limitation of the facility in our hospital.

In conclusion, visual recovery in Taiwanese children with optic neuritis is favorable; a poor visual outcome was associated with age older than 10 years and pale disc at presentation. In addition, relatively lower rate of developing MS and not uncommon association with ADEM were also noted in Taiwanese children with optic neuritis.

graphic file with name eye2011196i1.jpg

The authors declare no conflict of interest.

References

  1. Beck RW, Cleary PA, Anderson MM, Jr, Keltner JL, Shults WT, Kaufman DI, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The optic neuritis study group. N Engl J Med. 1992;326:581–588. doi: 10.1056/NEJM199202273260901. [DOI] [PubMed] [Google Scholar]
  2. Beck RW, Cleary PA. Optic neuritis treatment trial. One-year follow-up results. Arch Ophthalmol. 1993;111:773–775. doi: 10.1001/archopht.1993.01090060061023. [DOI] [PubMed] [Google Scholar]
  3. Visual function 15 years after optic neuritis: a final follow-up report from the optic neuritis treatment trial. Ophthalmology. 2008;115:1079–1082. doi: 10.1016/j.ophtha.2007.08.004. [DOI] [PubMed] [Google Scholar]
  4. Beck RW, Cleary PA, Trobe JD, Kaufman DI, Kupersmith MJ, Paty DW, et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. N Engl J Med. 1993;329:1764–1769. doi: 10.1056/NEJM199312093292403. [DOI] [PubMed] [Google Scholar]
  5. Beck RW, Gal RL. Treatment of acute optic neuritis: a summary of findings from the optic neuritis treatment trial. Arch Ophthalmol. 2008;126:994–995. doi: 10.1001/archopht.126.7.994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol. 2008;65:727–732. doi: 10.1001/archneur.65.6.727. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Trobe JD. High-dose corticosteroid regimen retards development of multiple sclerosis in optic neuritis treatment trial. Arch Ophthalmol. 1994;112:35–36. doi: 10.1001/archopht.1994.01090130045014. [DOI] [PubMed] [Google Scholar]
  8. Brady KM, Brar AS, Lee AG, Coats DK, Paysse EA, Steinkuller PG. Optic neuritis in children: clinical features and visual outcome. J AAPOS. 1999;3:98–103. doi: 10.1016/s1091-8531(99)70078-9. [DOI] [PubMed] [Google Scholar]
  9. Morales DS, Siatkowski RM, Howard CW, Warman R. Optic neuritis in children. J Pediatr Ophthalmol Strabismus. 2000;37:254–259. [PubMed] [Google Scholar]
  10. Cassidy L, Taylor D. Pediatric optic neuritis. J AAPOS. 1999;3:68–69. doi: 10.1016/s1091-8531(99)70072-8. [DOI] [PubMed] [Google Scholar]
  11. Riikonen R, Donner M, Erkkila H. Optic neuritis in children and its relationship to multiple sclerosis: a clinical study of 21 children. Dev Med Child Neurol. 1988;30:349–359. doi: 10.1111/j.1469-8749.1988.tb14560.x. [DOI] [PubMed] [Google Scholar]
  12. Kriss A, Francis DA, Cuendet F, Halliday AM, Taylor DS, Wilson J, et al. Recovery after optic neuritis in childhood. J Neurol Neurosurg Psychiatry. 1988;51:1253–1258. doi: 10.1136/jnnp.51.10.1253. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kennedy C, Csarroll FD. Optic neuritis in children. Arch Ophthalmol. 1960;63:747–755. doi: 10.1001/archopht.1960.00950020749001. [DOI] [PubMed] [Google Scholar]
  14. Visudhiphan P, Chiemchanya S, Santadusit S. Optic neuritis in children: recurrence and subsequent development of multiple sclerosis. Pediatr Neurol. 1995;13:293–295. doi: 10.1016/0887-8994(95)00188-3. [DOI] [PubMed] [Google Scholar]
  15. Hwang JM, Lee YJ, Kim MK. Optic neuritis in Asian children. J Pediatr Ophthalmol Strabismus. 2002;39:26–32. doi: 10.3928/0191-3913-20020101-07. [DOI] [PubMed] [Google Scholar]
  16. Hwang JS, Kim SJ, Yu YS, Chung H. Clinical characteristics of multiple sclerosis and associated optic neuritis in Korean children. J AAPOS. 2007;11:559–563. doi: 10.1016/j.jaapos.2007.04.021. [DOI] [PubMed] [Google Scholar]
  17. Mizota A, Niimura M, Adachi-Usami E. Clinical characteristics of Japanese children with optic neuritis. Pediatr Neurol. 2004;31:42–45. doi: 10.1016/j.pediatrneurol.2003.11.011. [DOI] [PubMed] [Google Scholar]
  18. Takihara Y, Inatani M, Fukushima M, Iwao K, Iwao M, Tanihara H. Trabeculectomy with mitomycin C for neovascular glaucoma: prognostic factors for surgical failure. Am J Ophthalmol. 2009;147:912–918. doi: 10.1016/j.ajo.2008.11.015. [DOI] [PubMed] [Google Scholar]
  19. Jo DH, Kim SJ, Chae JH, Yu YS. The clinical characteristics of optic neuritis in Korean children. Korean J Ophthalmol. 2011;25:116–120. doi: 10.3341/kjo.2011.25.2.116. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Boomer JA, Siatkowski RM. Optic neuritis in adults and children. Semin Ophthalmol. 2003;18:174–180. doi: 10.1080/08820530390895172. [DOI] [PubMed] [Google Scholar]
  21. Murphy J, Austin J. Spontaneous infection or vaccination as cause of acute disseminated encephalomyelitis. Neuroepidemiology. 1985;4:138–145. doi: 10.1159/000110225. [DOI] [PubMed] [Google Scholar]
  22. Lee WT, Wang PJ, Liu HM, Young C, Tseng CL, Chang YC, et al. Acute disseminated encephalomyelitis in children: clinical, neuroimaging and neurophysiologic studies. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi. 1996;37:197–203. [PubMed] [Google Scholar]
  23. Schwarz S, Mohr A, Knauth M, Wildemann B, Storch-Hagenlocher B. Acute disseminated encephalomyelitis: a follow-up study of 40 adult patients. Neurology. 2001;56:1313–1318. doi: 10.1212/wnl.56.10.1313. [DOI] [PubMed] [Google Scholar]
  24. Tenembaum S, Chamoles N, Fejerman N. Acute disseminated encephalomyelitis: a long-term follow-up study of 84 pediatric patients. Neurology. 2002;59:1224–1231. doi: 10.1212/wnl.59.8.1224. [DOI] [PubMed] [Google Scholar]
  25. Hung KL, Liao HT, Tsai ML. Postinfectious encephalomyelitis: etiologic and diagnostic trends. J Child Neurol. 2000;15:666–670. doi: 10.1177/088307380001501005. [DOI] [PubMed] [Google Scholar]
  26. Hynson JL, Kornberg AJ, Coleman LT, Shield L, Harvey AS, Kean MJ. Clinical and neuroradiologic features of acute disseminated encephalomyelitis in children. Neurology. 2001;56:1308–1312. doi: 10.1212/wnl.56.10.1308. [DOI] [PubMed] [Google Scholar]
  27. Kotlus BS, Slavin ML, Guthrie DS, Kodsi SR. Ophthalmologic manifestations in pediatric patients with acute disseminated encephalomyelitis. J AAPOS. 2005;9:179–183. doi: 10.1016/j.jaapos.2004.10.009. [DOI] [PubMed] [Google Scholar]
  28. Toker E, Yenice O, Yilmaz Y. Isolated bilateral optic neuropathy in acute disseminated encephalomyelitis. J Pediatr Ophthalmol Strabismus. 2003;40:232–235. doi: 10.3928/0191-3913-20030701-13. [DOI] [PubMed] [Google Scholar]
  29. Straub J, Chofflon M, Delavelle J. Early high-dose intravenous methylprednisolone in acute disseminated encephalomyelitis: a successful recovery. Neurology. 1997;49:1145–1147. doi: 10.1212/wnl.49.4.1145. [DOI] [PubMed] [Google Scholar]
  30. Farris BK, Pickard DJ. Bilateral postinfectious optic neuritis and intravenous steroid therapy in children. Ophthalmology. 1990;97:339–345. doi: 10.1016/s0161-6420(90)32583-6. [DOI] [PubMed] [Google Scholar]
  31. Lucchinetti CF, Kiers L, O′Duffy A, Gomez MR, Cross S, Leavitt JA, et al. Risk factors for developing multiple sclerosis after childhood optic neuritis. Neurology. 1997;49:1413–1418. doi: 10.1212/wnl.49.5.1413. [DOI] [PubMed] [Google Scholar]
  32. Dale RC, de SC, Chong WK, Cox TC, Harding B, Neville BG. Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain. 2000;123 (Part 12:2407–2422. doi: 10.1093/brain/123.12.2407. [DOI] [PubMed] [Google Scholar]
  33. Kesselring J, Miller DH, Robb SA, Kendall BE, Moseley IF, Kingsley D, et al. Acute disseminated encephalomyelitis. MRI findings and the distinction from multiple sclerosis. Brain. 1990;113 (Part 2:291–302. doi: 10.1093/brain/113.2.291. [DOI] [PubMed] [Google Scholar]
  34. Biousse V, Calvetti O, Drews-Botsch CD, Atkins EJ, Sathornsumetee B, Newman NJ. Management of optic neuritis and impact of clinical trials: an international survey. J Neurol Sci. 2009;276:69–74. doi: 10.1016/j.jns.2008.08.039. [DOI] [PubMed] [Google Scholar]
  35. Morrissey SP, Miller DH, Kendall BE, Kingsley DP, Kelly MA, Francis DA, et al. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study. Brain. 1993;116 (Part 1:135–146. doi: 10.1093/brain/116.1.135. [DOI] [PubMed] [Google Scholar]

Articles from Eye are provided here courtesy of Nature Publishing Group

RESOURCES